Ipsen faces another setback for bone disorder drug with EMA panel’s rejection

European union flag against parliament in Brussels


A committee of the European Medicines Agency (EMA) declined to recommended Ipsen’s (OTCPK:IPSEY) (OTCPK:IPSEF) drug palovarotene for approval in EU to treat a rare bone disorder.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended not to grant marketing authorization

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!